T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
The Bancorp
TBBK
$2.82B
| $33.9M | ﹤0.01% |
897,301
-291,848
| -25% | -$9.64M |
|
827
Tenable Holdings
TENB
$4.41B
| $33.5M | ﹤0.01% |
768,659
-130,085
| -14% | -$5.74M |
|
828
Endava
DAVA
$167M
| $33.5M | ﹤0.01% |
1,145,472
-3,289,672
| -74% | -$97.6M |
|
829
RadNet
RDNT
$6.08B
| $33.4M | ﹤0.01% |
566,156
+531,102
| +1,515% | +$28.8M |
|
830
DTE Energy
DTE
$29B
| $33.2M | ﹤0.01% |
298,955
+4,997
| +2% | +$559K |
|
831
Constellium
CSTM
$3.95B
| $33.1M | ﹤0.01% |
1,756,223
+57,323
| +3% | +$1.19M |
|
832
Chemed
CHE
$7.02B
| $33.1M | ﹤0.01% |
60,930
-2,803
| -4% | -$1.61M |
|
833
AngloGold Ashanti
AU
$48.1B
| $32.9M | ﹤0.01% |
+1,310,820
| New | +$31.1M |
|
834
Relay Therapeutics
RLAY
$4.37B
| $32.9M | ﹤0.01% |
5,039,015
-1,840,582
| -27% | -$12.6M |
|
835
Alpha Metallurgical Resources
AMR
$1.97B
| $32.8M | ﹤0.01% |
116,957
+8,861
| +8% | +$2.74M |
|
836
Beam Therapeutics
BEAM
$2.74B
| $32.7M | ﹤0.01% |
1,393,673
+147,484
| +12% | +$3.62M |
|
|
DAWN
837
DELISTED
Day One Biopharmaceuticals
DAWN
| $32.4M | ﹤0.01% |
2,350,880
+51,116
| +2% | +$748K |
|
|
WRK
838
DELISTED
WestRock Company
WRK
| $32.1M | ﹤0.01% |
639,165
-1,265,209
| -66% | -$63.9M |
|
839
Nasdaq
NDAQ
$54.6B
| $32M | ﹤0.01% |
531,617
+14,617
| +3% | +$885K |
|
840
Federal Realty Investment Trust
FRT
$10.3B
| $32M | ﹤0.01% |
316,662
+7,559
| +2% | +$763K |
|
841
Blackbaud
BLKB
$2.1B
| $31.9M | ﹤0.01% |
418,648
+30,639
| +8% | +$2.36M |
|
|
CNTA
842
DELISTED
Centessa Pharmaceuticals
CNTA
| $31.9M | ﹤0.01% |
3,530,373
+572,294
| +19% | +$5.43M |
|
|
RAPP
843
Rapport Therapeutics
RAPP
$2.27B
| $31.6M | ﹤0.01% |
+1,360,605
| New | +$31.5M |
|
|
PWSC
844
DELISTED
PowerSchool Holdings, Inc.
PWSC
| $30.8M | ﹤0.01% |
1,377,060
+162,828
| +13% | +$3.28M |
|
845
Prestige Consumer Healthcare
PBH
$2.43B
| $30.7M | ﹤0.01% |
445,910
+79,751
| +22% | +$5.4M |
|
846
Braze
BRZE
$3.36B
| $30.5M | ﹤0.01% |
786,250
+64,605
| +9% | +$2.58M |
|
847
Donnelley Financial Solutions
DFIN
$1.22B
| $30.5M | ﹤0.01% |
511,390
+182,726
| +56% | +$11.2M |
|
848
Landstar System
LSTR
$6.4B
| $30.4M | ﹤0.01% |
164,908
-116,464
| -41% | -$21M |
|
849
Apogee Therapeutics
APGE
$10.2B
| $30.2M | ﹤0.01% |
768,221
-402,106
| -34% | -$19.5M |
|
850
Crocs
CROX
$6.36B
| $30.1M | ﹤0.01% |
206,080
+2,649
| +1% | +$372K |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.